UK Life-Sciences Sector Deal Brings Life And Funding To Industrial Strategy
The next step in the UK government's life-science strategy, the Life Sciences Sector Deal, was issued today, setting out a blueprint of government-support mechanisms and private investment across the whole of the sector. The deal, signaled yesterday at UK HealthTech 2017, seeks to maximize the potential of medtech and pharma businesses, and exploit the value of the NHS.
You may also be interested in...
UK Plugs Into ‘Golden Period’ For Medtech Innovation
The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.
UK Life Sciences Industrial Strategy Is Starting To Show Its Value In The Medtech Arena
UK strategies that have sought to maximize the partnership potential of medtech innovators and the country's National Health Service have often not lasted long enough to prove their worth. But Neil Mesher, Philips CEO of UK and Ireland, says the Life Sciences Industrial Strategy might just be different.
UK Device Manufacturers Must Contingency Plan For A Hard Brexit
The compromise tone adopted last week by the UK government on key "phase 1" issues of an EU-UK Brexit deal was welcomed by UK health-care products industries, but with uncertainty over phase 2 – the future EU trade deal – still hampering UK business planning, local companies have no choice but to begin contingencies for a hard Brexit. Overseas stakeholders are also starting to distance themselves from a UK still unable to commit to a post-2019 relationship with the EU27.